| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer D Cunningham, Y Humblet, S Siena, D Khayat, H Bleiberg, A Santoro, ... New England journal of medicine 351 (4), 337-345, 2004 | 6643 | 2004 |
| Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial AX Zhu, RS Finn, J Edeline, S Cattan, S Ogasawara, D Palmer, ... The Lancet Oncology 19 (7), 940-952, 2018 | 2363 | 2018 |
| Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A Vogel, A Cervantes, I Chau, B Daniele, JM Llovet, T Meyer, JC Nault, ... Annals of oncology 29, iv238-iv255, 2018 | 1022 | 2018 |
| Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer E Van Cutsem, H Van De Velde, P Karasek, H Oettle, WL Vervenne, ... Journal of clinical oncology 22 (8), 1430-1438, 2004 | 1011 | 2004 |
| Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer E Van Cutsem, WL Vervenne, J Bennouna, Y Humblet, S Gill, ... Journal of clinical oncology 27 (13), 2231-2237, 2009 | 819 | 2009 |
| Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease T Roskams, SQ Yang, A Koteish, A Durnez, R DeVos, X Huang, R Achten, ... The American journal of pathology 163 (4), 1301-1311, 2003 | 539 | 2003 |
| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 520 | 2023 |
| Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal … A Hendlisz, MV Eynde, M Peeters, G Maleux, B Lambert, J Vannoote, ... Journal of clinical oncology 28 (23), 3687-3694, 2010 | 514 | 2010 |
| The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin A Durnez, C Verslype, F Nevens, J Fevery, R Aerts, J Pirenne, E Lesaffre, ... Histopathology 49 (2), 138-151, 2006 | 507 | 2006 |
| Hepatocellular carcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up C Verslype, O Rosmorduc, P Rougier, ESMO Guidelines Working Group Annals of oncology 23, vii41-vii48, 2012 | 499 | 2012 |
| Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin M Komuta, B Spee, S Vander Borght, R De Vos, C Verslype, R Aerts, ... Hepatology 47 (5), 1544-1556, 2008 | 452 | 2008 |
| Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity K Vriens, S Christen, S Parik, D Broekaert, K Yoshinaga, A Talebi, ... Nature 566 (7744), 403-406, 2019 | 432 | 2019 |
| Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer J Tabernero, E Van Cutsem, E Díaz-Rubio, A Cervantes, Y Humblet, ... Journal of clinical oncology 25 (33), 5225-5232, 2007 | 412 | 2007 |
| Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes M Komuta, O Govaere, V Vandecaveye, J Akiba, W Van Steenbergen, ... Hepatology 55 (6), 1876-1888, 2012 | 395 | 2012 |
| Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines A Vogel, E Martinelli, A Cervantes, I Chau, B Daniele, JM Llovet, T Meyer, ... Annals of Oncology 32 (6), 801-805, 2021 | 349 | 2021 |
| Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study A Katoonizadeh, W Laleman, C Verslype, A Wilmer, G Maleux, ... Gut 59 (11), 1561-1569, 2010 | 348 | 2010 |
| Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver … W Laleman, A Wilmer, P Evenepoel, IV Elst, M Zeegers, Z Zaman, ... Critical Care 10, 1-13, 2006 | 347 | 2006 |
| Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules L Libbrecht, T Severi, D Cassiman, S Vander Borght, J Pirenne, F Nevens, ... The American journal of surgical pathology 30 (11), 1405-1411, 2006 | 339 | 2006 |
| Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma J Ricke, HJ Klümpen, H Amthauer, I Bargellini, P Bartenstein, EN de Toni, ... Journal of hepatology 71 (6), 1164-1174, 2019 | 333 | 2019 |
| Correction to:“Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up” A Vogel, A Cervantes, I Chau, B Daniele, JM Llovet, T Meyer, JC Nault, ... Annals of Oncology 30 (5), 871-873, 2019 | 299 | 2019 |